Nadunolimab combined with chemotherapy showed no significant efficacy improvement in metastatic TNBC, despite surpassing ...
The phase 3 MajesTEC-3 trial demonstrated that the combination of the bispecific BCMA-directed T-cell engager teclistamab and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback